BioCentury | Dec 14, 2009

Ebb & Flow

Investors in oncology company Gloucester Pharmaceuticals Inc. are looking at a 3.5X-6.5X return on an acquisition by Celgene Corp. (NASDAQ: CELG), making it a model for how to execute in-licensing and keep costs under control....
BC Extra | Dec 11, 2009
Financial News

China Nuokang prices IPO

China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) raised $40.7 million through the sale of 4.5 million American Depositary Shares at $9 per ADS in an IPO underwritten by Jefferies and Oppenheimer. The deal came in below the...
BioCentury | Dec 7, 2009

Ebb & Flow

The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus. Indeed, if all goes well,...
BC Extra | Nov 24, 2009
Top Story

Ironwood, China Nuokang planning IPOs

Ironwood Pharmaceuticals Inc . (Cambridge, Mass.) and China Nuokang Bio-Pharmaceutical Inc. (Shenyang, China) filed for IPOs on Friday. Ironwood filed to raise up to $172.5 million in an IPO underwritten by JPMorgan; Morgan Stanley; Credit Suisse;...
Items per page:
1 - 4 of 4